1.91

3.80% 0.07

Larimar Therapeutics Inc (LRMR)

Overview News Price History Option Chain Financials Discussions Forecast

Larimar Therapeutics Inc stock is traded at $1.91, with a volume of 1.09M. It is up +3.80% in the last 24 hours and down -25.10% over the past month. Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Previous Close:

$1.84

Open:

$1.86

24h Volume:

1.09M

Relative Volume:

1.52

Market Cap:

$119.73M

Revenue:

Net Income/Loss:

$-36.95M

P/E Ratio:

-2.2738

EPS:

-0.84

Net Cash Flow:

$-33.46M

1W Performance:

+7.30%

1M Performance:

-25.10%

6M Performance:

-75.67%

1Y Performance:

-72.91%

1-Day Range:

$1.86

$1.97

1-Week Range:

$1.73

$1.97

52-Week Range:

$1.61

$11.20

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name

Larimar Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

844-511-9056

Address

THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA

Employee

Twitter

Next Earnings Date

2025-03-24

Latest SEC Filings

LRMR's Discussions on Twitter

Compare LRMR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LRMR Larimar Therapeutics Inc	1.91	119.73M	0	-36.95M	-33.46M	-0.84
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-25	Initiated	Truist	Buy
Oct-16-24	Initiated	Oppenheimer	Outperform
Oct-03-24	Initiated	Wedbush	Outperform
Oct-02-24	Initiated	H.C. Wainwright	Buy
Sep-04-24	Initiated	Robert W. Baird	Outperform
Apr-03-24	Initiated	Leerink Partners	Outperform
Nov-17-23	Upgrade	Citigroup	Neutral → Buy
Oct-19-22	Initiated	Guggenheim	Buy
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform

View All

Larimar Therapeutics Inc Stock (LRMR) Latest News

Apr 04, 2025

Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha

Apr 04, 2025

Apr 03, 2025

An In-Depth Look at Larimar Therapeutics Inc Inc. (LRMR) Price Performance During Market Crashes - investchronicle.com

Apr 03, 2025

Apr 01, 2025

Larimar to seek accelerated approval of FA therapy nomlabofusp this year - Friedreich's Ataxia News

Apr 01, 2025

Mar 31, 2025

Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst - MarketBeat

Mar 31, 2025

Mar 28, 2025

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance

Mar 28, 2025

Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support - MSN

Mar 28, 2025

Mar 26, 2025

Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim - Defense World

Mar 26, 2025

HC Wainwright Issues Positive Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price - Defense World

Mar 26, 2025

Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. Baird - Defense World

Mar 26, 2025

Mar 25, 2025

Jones Trading maintains $14 target on Larimar Therapeutics stock By Investing.com - Investing.com UK

Mar 25, 2025

Larimar Therapeutics Reports 2024 Financial Results and Development Progress - TipRanks

Mar 25, 2025

Mar 24, 2025

FDA open to new surrogate endpoint for FA drug approval By Investing.com - Investing.com Australia

Mar 24, 2025

Larimar: Q4 Earnings Snapshot - mySA

Mar 24, 2025

Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating - MarketScreener

Mar 24, 2025

FDA open to new surrogate endpoint for FA drug approval - Investing.com India

Mar 24, 2025

Larimar: Q4 Earnings Snapshot -March 24, 2025 at 07:17 am EDT - MarketScreener

Mar 24, 2025

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 24, 2025

Breakthrough: FDA Opens Door for Faster Approval of Larimar's Rare Disease Treatment - Stock Titan

Mar 24, 2025

Mar 14, 2025

Larimar Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView

Mar 14, 2025

Mar 08, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MSN

Mar 08, 2025

Mar 03, 2025

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire

Mar 03, 2025

Will Larimar's Rare Disease Pipeline Updates Move the Needle? Key Investor Conference Coming - StockTitan

Mar 03, 2025

Ataxia Market Is Booming Worldwide 2025-2032 | Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics - openPR.com

Mar 03, 2025

Feb 26, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages - The AM Reporter

Feb 26, 2025

Feb 25, 2025

Financial Metrics Exploration: Understanding Larimar Therapeutics Inc (LRMR) Through Ratios - The Dwinnex

Feb 25, 2025

Feb 14, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Boosted by SG Americas Securities LLC - Defense World

Feb 14, 2025

Feb 12, 2025

Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St

Feb 12, 2025

Feb 05, 2025

BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com

Feb 05, 2025

Insider’s View: Deciphering Larimar Therapeutics Inc (LRMR)’s Financial Health Through Ratios - The Dwinnex

Feb 05, 2025